Investigating hemophagocytosis in critically ill adults
Hemophagocytosis in Critically Ill Adult Patients With Cytopenias
University of Ulm · NCT01913938
This study is trying to see if critically ill adults with low blood cell counts and signs of a serious condition called hemophagocytic lymphohistiocytosis respond to a specific treatment to help improve their situation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | University of Ulm (other) |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Ulm and 1 other locations) |
| Trial ID | NCT01913938 on ClinicalTrials.gov |
What this trial studies
This observational study aims to determine the relationship between non-responsiveness to recombinant human granulocyte colony-stimulation factor (rhG-CSF) and hemophagocytosis in critically ill adult patients experiencing cytopenias. It focuses on whether adults with bicytopenia or pancytopenia who meet clinical criteria for hemophagocytic lymphohistiocytosis (HLH) exhibit life-threatening hemophagocytosis. The study will analyze the responsiveness to rhG-CSF therapy in these patients to better understand the condition's implications.
Who should consider this trial
Good fit: Ideal candidates for this study are critically ill adults over 18 years old with leukopenia and thrombocytopenia receiving rhG-CSF therapy.
Not a fit: Patients with a life expectancy of less than 24 hours, those involved in other studies, or those with certain hematologic disorders or malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the understanding and management of hemophagocytosis in critically ill adults, potentially leading to better treatment strategies.
How similar studies have performed: While hemophagocytosis has been studied primarily in children, this approach in adults is less explored, making it a novel investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age \> 18 years * critically ill adult patients * leukopenia and thrombocytopenia * rhG-CSF therapy Exclusion Criteria: * life expectancy \< 24 hours * inclusion in other studies * trauma patients with reanimation on scene or immediately dying on hospital admission * pregnancy * hematologic disorder, malignancy * high dose corticosteroid treatment or chemotherapy
Where this trial is running
Ulm and 1 other locations
- Department of Anaesthesiology, University Hospital Ulm — Ulm, Germany (RECRUITING)
- Department of Internal Medicine III, Comprehensive Infectious Disease Center, University Hospital Ulm, Germany — Ulm, Germany (RECRUITING)
Study contacts
- Principal investigator: Manfred E Weiss, MD — Department of Anesthesiology
- Study coordinator: Manfred E Weiss, MD
- Email: manfred.weiss@uniklinik-ulm.de
- Phone: 49-731-50060226
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hemophagocytosis, Hemophagocytosis, adults, rhG-CSF